50893-83-9

Upstream product

• 56681-66-4 3-methoxy-4-acetoxybenzoyl chloride 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 54771-60-7 4-acetyl-2-methoxyphenyl acetate 
• 108-24-7 acetic anhydride 
• 74162-07-5 4-(2-diazoacetyl)-2-methoxyphenyl acetate 

Downstream Products

• 52041-25-5 4-Acetoxy-3-methoxy-ω(2,6-dimethoxyphenoxy)-acetophenon 
• 50893-84-0 α-Thioacetoxy-4-acetoxy-3-methoxy-acetophenon 
• 6344-28-1 2-chloro-1-(4-hydroxy-3-methoxyphenyl)ethan-1-one 
• 37803-48-8 β-oxo-β-(3,4-dimethoxyphenyl)-ethanol 
• 18256-48-9 2,4'-dihydroxy-3'-methoxyacetophenone 
• 139473-80-6 2-acetoxy-1-(4-hydroxy-3-methoxy-phenyl)-ethanone 
• 237384-77-9 2-methoxy-4-{2-[5-(methoxycarbonyl)-2-methylthio(3-thienyl)](1,3-thiazol-4-yl)}phenyl acetate 
• 1018948-88-3 2-methoxy-4-[-2-(methylthio)acetyl]phenyl acetate 
• 52041-24-4 1-hydroxy-1-(4-hydroxy-3-methoxy-phenyl)-2-(2,6-dimethoxyphenoxy)ethane 
• 52041-31-3 Acetic acid 2'-{2-acetoxy-5-[1-acetoxy-2-(2,6-dimethoxy-phenoxy)-ethyl]-3-methoxy-phenoxy}-5,5'-bis-[1-acetoxy-2-(2,6-dimethoxy-phenoxy)-ethyl]-3,3'-dimethoxy-biphenyl-2-yl ester 
• 5155-61-3 1-<4-Hydroxy-3-methoxy-phenyl>-2-monothioethylenglycol 

Relevant academic research and scientific papers

NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF

The present invention relates to the novel benzofuran derivatives, the preparation thereof and the composition comprising the same. The benzofuran derivatives of the present invention showed potent inhibiting activity of beta-amyloid aggregation and cell cytotoxicity resulting in stimulating the proliferation of neuronal cells as well as recovering activity of memory learning injury caused by neuronal cell injury using transformed animal model with beta-amyloid precursor gene, therefore the compounds can be useful in treating or preventing cognitive function disorder.

Compounds and compositons for treating C1s-mediated diseases and conditions

Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4, X, Y and Z are defined in the specification.

Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors

The present invention is directed to compounds of Formula I: wherein X is O, S or NR7and R1-R7, Y and Z are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, plasmin and urokinase. Certain of the compounds exhibit direct, selective inhibition of urokinase, or are intermediates useful for forming compounds having such activity.